Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

NCT04324112 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

NIH

Sponsor class

Conditions

Hairy Cell Leukemia

Interventions

DRUG: binimetinib
DRUG: Encorafenib

Sponsor

National Cancer Institute (NCI)